Breast Cancer Outcomes

Breast Measures	Expected Estimated Performance Rates (percentage)	Yale Performance 2017	Yale Performance 2018	Yale Performance 2019
Tamoxifen or third generation aromotase inhibitor is recommended or administered within 1 year (365 days) of diagnosis for women with AJCC T1cN0M0 or stage IB-III hormone receptor positive breast cancer (Accountability)	90%	92.3	94.9	90.8
Radiation therapy is recommended or administered following any mastectomy within 1 year (365 days) of diagnosis of breast cancer for women with >= 4 positive regional lymph nodes (Accountability)	90%	84.2*	100	100
Radiation is administered within 1 year (365 days) of diagnosis for women under the age of 70 receiving breast conservation surgery for breast cancer (Accountability)	90%	93	95.1	94
Combination chemotherapy is considered or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cN0, or stage IB - III hormone receptor negative breast cancer (Accountability)	90%	90.9	96.5	100

*Total of 3/19 patients received radiation, but occurred more than 1 year after diagnosis (Reasons: (a) 2 patients the decision was to add more chemo s/p neoadjuvant followed by mastectomy due to disease extension; (b) XRT delayed as a patient required an ostomy for an unrelated condition).